BRPI0811476A2 - Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível - Google Patents

Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível

Info

Publication number
BRPI0811476A2
BRPI0811476A2 BRPI0811476-5A2A BRPI0811476A BRPI0811476A2 BR PI0811476 A2 BRPI0811476 A2 BR PI0811476A2 BR PI0811476 A BRPI0811476 A BR PI0811476A BR PI0811476 A2 BRPI0811476 A2 BR PI0811476A2
Authority
BR
Brazil
Prior art keywords
reversible
intravenous
inhibitor
direct
oral dosage
Prior art date
Application number
BRPI0811476-5A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert M Scarborough
Daniel D Gretler
Pamela B Conley
Patrick Andre
Athiwat Hutchaleelaha
David R Philips
Anjali Pandey
Huang Wolin
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of BRPI0811476A2 publication Critical patent/BRPI0811476A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0811476-5A2A 2007-05-02 2008-05-02 Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível BRPI0811476A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (1)

Publication Number Publication Date
BRPI0811476A2 true BRPI0811476A2 (pt) 2014-11-04

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811476-5A2A BRPI0811476A2 (pt) 2007-05-02 2008-05-02 Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível

Country Status (17)

Country Link
US (2) US20090048216A1 (https=)
EP (1) EP2079464A2 (https=)
JP (1) JP2010526101A (https=)
KR (1) KR20100029746A (https=)
CN (1) CN101795682A (https=)
AU (1) AU2008247483A1 (https=)
BR (1) BRPI0811476A2 (https=)
CA (1) CA2686203A1 (https=)
CO (1) CO6241104A2 (https=)
EA (1) EA200901473A1 (https=)
EC (1) ECSP099778A (https=)
GT (1) GT200900284A (https=)
IL (1) IL201834A0 (https=)
MA (1) MA31663B1 (https=)
MX (1) MX2009011843A (https=)
TN (1) TN2009000451A1 (https=)
WO (1) WO2008137753A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1951254E (pt) * 2005-11-03 2012-04-12 Portola Pharm Inc [4-(6-halo-7-substituído-2,4-dioxo-1,4-di-hidro-2hquinazolin- 3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilureias e formas e métodos relacionados com as mesmas
CA2678492A1 (en) * 2007-03-06 2008-09-12 Novartis Ag Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
WO2008137809A2 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
MX2011006995A (es) * 2008-12-30 2011-09-27 Thrombologic Aps Metodos para identificar pacientes criticamente enfermos en riesgo incrementado de desarrollar nsuficiencia organica y compuestos para el tratamiento de la misma.
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2633857B1 (en) * 2009-12-23 2015-08-12 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor and acetylsalicylic acid
US20130165459A1 (en) 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
EP2646827A1 (en) 2010-12-01 2013-10-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and kits for determining platelet susceptibility to activation in a patient
JP2013544271A (ja) * 2010-12-03 2013-12-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法
MA49887A (fr) 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12
MA49452A (fr) 2017-06-23 2021-05-05 Chiesi Farm Spa Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
PT1951254E (pt) 2005-11-03 2012-04-12 Portola Pharm Inc [4-(6-halo-7-substituído-2,4-dioxo-1,4-di-hidro-2hquinazolin- 3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilureias e formas e métodos relacionados com as mesmas

Also Published As

Publication number Publication date
JP2010526101A (ja) 2010-07-29
KR20100029746A (ko) 2010-03-17
US20090048216A1 (en) 2009-02-19
CO6241104A2 (es) 2011-01-20
GT200900284A (es) 2012-01-31
WO2008137753A3 (en) 2009-02-12
CN101795682A (zh) 2010-08-04
EP2079464A2 (en) 2009-07-22
EA200901473A1 (ru) 2010-06-30
US20120009172A1 (en) 2012-01-12
MX2009011843A (es) 2010-04-22
TN2009000451A1 (en) 2011-03-31
AU2008247483A1 (en) 2008-11-13
MA31663B1 (fr) 2010-09-01
WO2008137753A2 (en) 2008-11-13
IL201834A0 (en) 2010-06-16
CA2686203A1 (en) 2008-11-13
ECSP099778A (es) 2010-01-29

Similar Documents

Publication Publication Date Title
BRPI0811476A2 (pt) Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível
DK2277509T3 (da) DPP IV inhibitorformuleringer
EP2047820A4 (en) ORTHODONTIC FASTENING BRIDGE
CY2014011I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
BRPI0918360A2 (pt) composto, composição farmacêutica e usos de um composto
EP2133096A4 (en) IN THE MOUTHING TABLET
EP2132133A4 (en) RELEASE OF PARTICULATE ACTIVE SUBSTANCES
DK2384754T3 (da) Farmaceutiske doseringsformer
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
EP2147437A4 (en) SEEDING REPLICATION
EP2320893A4 (en) COMBINATION OF A TRIPTAN AND AN NSAR
PT2397142T (pt) Utilizações de inibidores da dpp iv
DK2077729T3 (da) Orale probiotiske doseringsformer
BRPI0716365A2 (pt) "artigo odontolàgico"
BRPI1011587A2 (pt) compostos e composições terapèuticas
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
GB0703438D0 (en) Preventing spread of infection
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
BRPI0819232A2 (pt) composto heterocíclico e composição farmacêutica do mesmo
HRP20192282T8 (hr) Inhibitori tfpi i postupci upotrebe
DK2018158T3 (da) Ny racecadotril administrationsform
EP2185112A4 (en) Stabilized therapeutic compositions and formulations
DE602007010119D1 (de) Mundpflegezusammensetzung mit silikonverbund
IL192319A (en) Assessment of medical conditions
IL202765A0 (en) Pharmaceutical combination of nsaid and prostaglandin compound

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]